Antiandrogenic therapy can cause coronary arterial disease

Kuan Chou Chen, Chiung Chi Peng, Hsiu Mei Hsieh, Chiung Huei Peng, Chiu Lan Hsieh, Chien Ning Huang, Charng Cherng Chyau, Hui Er Wang, Robert Y. Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

Original languageEnglish
Pages (from-to)886-891
Number of pages6
JournalInternational Journal of Urology
Volume12
Issue number10
DOIs
Publication statusPublished - 2005 Oct 1

Fingerprint

Cyproterone Acetate
Coronary Disease
Apolipoprotein A-II
Apolipoprotein A-I
Prostatic Neoplasms
Triglycerides
Apolipoprotein B-100
Androgen Antagonists
Neoplasm Grading
Therapeutics
Lipid Metabolism
HDL Cholesterol
Lipoproteins
Coronary Artery Disease
Estrogens
Radiotherapy
Cholesterol
Incidence

Keywords

  • Antiandrogen
  • CAD (coronary arterial disease)
  • CPA (cyproterone acetate)
  • Hormonal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Chen, K. C., Peng, C. C., Hsieh, H. M., Peng, C. H., Hsieh, C. L., Huang, C. N., ... Peng, R. Y. (2005). Antiandrogenic therapy can cause coronary arterial disease. International Journal of Urology, 12(10), 886-891. https://doi.org/10.1111/j.1442-2042.2005.01145.x

Antiandrogenic therapy can cause coronary arterial disease. / Chen, Kuan Chou; Peng, Chiung Chi; Hsieh, Hsiu Mei; Peng, Chiung Huei; Hsieh, Chiu Lan; Huang, Chien Ning; Chyau, Charng Cherng; Wang, Hui Er; Peng, Robert Y.

In: International Journal of Urology, Vol. 12, No. 10, 01.10.2005, p. 886-891.

Research output: Contribution to journalArticle

Chen, KC, Peng, CC, Hsieh, HM, Peng, CH, Hsieh, CL, Huang, CN, Chyau, CC, Wang, HE & Peng, RY 2005, 'Antiandrogenic therapy can cause coronary arterial disease', International Journal of Urology, vol. 12, no. 10, pp. 886-891. https://doi.org/10.1111/j.1442-2042.2005.01145.x
Chen, Kuan Chou ; Peng, Chiung Chi ; Hsieh, Hsiu Mei ; Peng, Chiung Huei ; Hsieh, Chiu Lan ; Huang, Chien Ning ; Chyau, Charng Cherng ; Wang, Hui Er ; Peng, Robert Y. / Antiandrogenic therapy can cause coronary arterial disease. In: International Journal of Urology. 2005 ; Vol. 12, No. 10. pp. 886-891.
@article{bc77ec8a7d584221826da335413cb1e3,
title = "Antiandrogenic therapy can cause coronary arterial disease",
abstract = "Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6{\%} as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.",
keywords = "Antiandrogen, CAD (coronary arterial disease), CPA (cyproterone acetate), Hormonal therapy, Prostate cancer",
author = "Chen, {Kuan Chou} and Peng, {Chiung Chi} and Hsieh, {Hsiu Mei} and Peng, {Chiung Huei} and Hsieh, {Chiu Lan} and Huang, {Chien Ning} and Chyau, {Charng Cherng} and Wang, {Hui Er} and Peng, {Robert Y.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1111/j.1442-2042.2005.01145.x",
language = "English",
volume = "12",
pages = "886--891",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Antiandrogenic therapy can cause coronary arterial disease

AU - Chen, Kuan Chou

AU - Peng, Chiung Chi

AU - Hsieh, Hsiu Mei

AU - Peng, Chiung Huei

AU - Hsieh, Chiu Lan

AU - Huang, Chien Ning

AU - Chyau, Charng Cherng

AU - Wang, Hui Er

AU - Peng, Robert Y.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

AB - Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

KW - Antiandrogen

KW - CAD (coronary arterial disease)

KW - CPA (cyproterone acetate)

KW - Hormonal therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=28444464037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444464037&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2005.01145.x

DO - 10.1111/j.1442-2042.2005.01145.x

M3 - Article

C2 - 16323982

AN - SCOPUS:28444464037

VL - 12

SP - 886

EP - 891

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 10

ER -